Breast Cancer Core Needle Biopsy Market Size, Share & Trends Analysis Report By Technology, By End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), By Region, And Segment Forecasts, 2025 - 2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,950	150 Pages	Grand View Research	January, 2025	GV19584219

Best Price Guarantee
Price	from $5,950
Length	150 Pages
Publisher	Grand View Research
Published Date	January, 2025
SKU	GV19584219

Table of Contents
Description

Breast Cancer Core Needle Biopsy Market Growth & Trends

The global breast cancer core needle biopsy market size is estimated to reach USD 1.15 billion by 2030, registering to grow at a CAGR of 4.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. The market growth is primarily propelled by factors such as the increasing prevalence of breast cancer, the widespread recommendations for regular mammography screenings, rising awareness among individuals, and extensive research studies conducted in this field. These factors collectively contribute to the rising demand and adoption of breast cancer core needle biopsy procedures, paving the way for significant growth in the coming years.

Additionally, continuous advancements in imaging technologies and biopsy techniques contribute to the expansion of the industry. There is a growing recognition of the crucial role that early detection and diagnosis play in improving patient outcomes. Core needle biopsies offer distinct advantages over traditional open surgical biopsies, including reduced invasiveness, quicker recovery time, and cost-effectiveness.

As the demand for early detection and diagnosis continues to rise, the market for breast cancer core needle biopsy is expected to witness significant growth. A recent example of innovative research in this field involves the use of contrast-mammography-guided breast biopsies that utilize MRI technology for lesion visualization, as demonstrated by researchers at the IMIM (Hospital del Mar Medical Research Institute) in Spain, in 2022 with the findings published in the journal European Radiology.

The COVID-19 pandemic has both challenged and opened new opportunities in the breast cancer core needle biopsy market. Delays in non-essential procedures have led to a decrease in diagnosis rate and demand for core needle biopsies. However, the pandemic has emphasized the importance of early detection, leading healthcare providers to prioritize screenings and biopsies, resulting in a resurgence in demand.

Breast Cancer Core Needle Biopsy Market Report Highlights

The ultrasound-based breast biopsy segment accounted for the largest revenue share of 41.9% in 2024. The segment dominance can be attributed to the growing preference for ultrasound-guided biopsies due to their notable advantages.
The hospitals & diagnostic laboratories segment captured the highest revenue share of 60.0% in 2024.
The academic & research institutes segment is predicted to grow at an exponential CAGR of 4.4% from 2025 to 2030 in the breast cancer core needle biopsy industry.
North America breast cancer core needle biopsy industry dominated and accounted for a 46.26%of revenue share in 2024.

Please note The report will be delivered in 2-3 business days upon order notification.

Chapter 1. Methodology and Scope: 1.1. Market Segmentation & Scope; 1.2. Segment Definitions; 1.2.1. Technology; 1.2.2. End use; 1.2.3. Regional scope; 1.2.4. Estimates and forecasts timeline; 1.3. Research Methodology; 1.4. Information Procurement; 1.4.1. Purchased database; 1.4.2. GVR’s internal database; 1.4.3. Secondary sources; 1.4.4. Primary research; 1.4.5. Details of primary research; 1.4.5.1. Data for primary interviews in North America; 1.4.5.2. Data for primary interviews in Europe; 1.4.5.3. Data for primary interviews in Asia Pacific; 1.4.5.4. Data for primary interviews in Latin America; 1.4.5.5. Data for Primary interviews in MEA; 1.5. Information or Data Analysis; 1.5.1. Data analysis models; 1.6. Market Formulation & Validation; 1.7. Model Details; 1.7.1. Commodity flow analysis (Model 1); 1.7.2. Approach 1: Commodity flow approach; 1.7.3. Volume price analysis (Model 2); 1.7.4. Approach 2: Volume price analysis; 1.8. List of Secondary Sources; 1.9. List of Primary Sources; 1.10. Objectives
Chapter 2. Executive Summary: 2.1. Market Outlook; 2.2. Segment Outlook; 2.2.1. Technology outlook; 2.2.2. End use outlook; 2.2.3. Regional outlook; 2.3. Competitive Insights
Chapter 3. Breast Cancer Core Needle Biopsy Market Variables, Trends & Scope: 3.1. Market Lineage Outlook; 3.1.1. Parent market outlook; 3.1.2. Related/ancillary market outlook; 3.2. Market Dynamics; 3.2.1. Market driver analysis; 3.2.1.1. Growing prevalence of breast cancer; 3.2.1.2. Advancement in imaging technologies and biopsy techniques; 3.2.1.3. Rising inclination towards minimally invasive procedures; 3.2.2. Market restraint analysis; 3.2.2.1. High cost of core needle biopsy procedures; 3.2.2.2. Limited expertise and training; 3.3. Breast Cancer Core Needle Biopsy Market Analysis Tools; 3.3.1. Industry Analysis - Porter’s; 3.3.1.1. Supplier power; 3.3.1.2. Buyer power; 3.3.1.3. Substitution threat; 3.3.1.4. Threat of new entrant; 3.3.1.5. Competitive rivalry; 3.3.2. PESTEL Analysis; 3.3.2.1. Political landscape; 3.3.2.2. Technological landscape; 3.3.2.3. Economic landscape
Chapter 4. Breast Cancer Core Needle Biopsy Market: Technology Estimates & Trend Analysis: 4.1. Technology Market Share, 2024 & 2030; 4.2. Segment Dashboard; 4.3. Global Breast Cancer Core Needle Biopsy Market by Technology Outlook; 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following; 4.4.1. MRI-Based Breast Biopsy; 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million); 4.4.2. Fermentation Ultrasound-Based Breast Biopsy; 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million); 4.4.3. Mammography-Based (Stereotactic) Breast Biopsy; 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million); 4.4.4. CT-Based Breast Biopsy; 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million); 4.4.5. Other Image-Based Breast Biopsy; 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Breast Cancer Core Needle Biopsy Market: End Use Estimates & Trend Analysis: 5.1. End Use Market Share, 2024 & 2030; 5.2. Segment Dashboard; 5.3. Global Breast Cancer Core Needle Biopsy Market by End Use Outlook; 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following; 5.4.1. Hospitals & Diagnostic Laboratories; 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million); 5.4.2. Pharmaceutical & Biotechnology companies; 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million); 5.4.3. Academic & Research Institutes; 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Breast Cancer Core Needle Biopsy Market: Regional Estimates & Trend Analysis: 6.1. Regional Market Share Analysis, 2024 & 2030; 6.2. Regional Market Dashboard; 6.3. Global Regional Market Snapshot; 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:; 6.5. North America; 6.5.1. U.S.; 6.5.1.1. Key country dynamics; 6.5.1.2. Regulatory framework/ reimbursement structure; 6.5.1.3. Competitive scenario; 6.5.1.4. Target Disease Prevalence; 6.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million); 6.5.2. Canada; 6.5.2.1. Key country dynamics; 6.5.2.2. Regulatory framework/ reimbursement structure; 6.5.2.3. Target Disease Prevalence; 6.5.2.4. Competitive scenario; 6.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million); 6.5.3. Mexico; 6.5.3.1. Key country dynamics; 6.5.3.2. Regulatory framework/ reimbursement structure; 6.5.3.3. Target Disease Prevalence; 6.5.3.4. Competitive scenario; 6.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million; 6.6. Europe; 6.6.1. UK; 6.6.1.1. Key country dynamics; 6.6.1.2. Regulatory framework/ reimbursement structure; 6.6.1.3. Target Disease Prevalence; 6.6.1.4. Competitive scenario; 6.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million); 6.6.2. Germany; 6.6.2.1. Key country dynamics; 6.6.2.2. Regulatory framework/ reimbursement structure; 6.6.2.3. Target Disease Prevalence; 6.6.2.4. Competitive scenario; 6.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million); 6.6.3. France; 6.6.3.1. Key country dynamics; 6.6.3.2. Regulatory framework/ reimbursement structure; 6.6.3.3. Target Disease Prevalence; 6.6.3.4. Competitive scenario; 6.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million); 6.6.4. Italy; 6.6.4.1. Key country dynamics; 6.6.4.2. Regulatory framework/ reimbursement structure; 6.6.4.3. Target Disease Prevalence; 6.6.4.4. Competitive scenario; 6.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million); 6.6.5. Spain; 6.6.5.1. Key country dynamics; 6.6.5.2. Regulatory framework/ reimbursement structure; 6.6.5.3. Target Disease Prevalence; 6.6.5.4. Competitive scenario; 6.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million); 6.6.6. Norway; 6.6.6.1. Key country dynamics; 6.6.6.2. Regulatory framework/ reimbursement structure; 6.6.6.3. Target Disease Prevalence; 6.6.6.4. Competitive scenario; 6.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million); 6.6.7. Sweden; 6.6.7.1. Key country dynamics; 6.6.7.2. Regulatory framework/ reimbursement structure; 6.6.7.3. Target Disease Prevalence; 6.6.7.4. Competitive scenario; 6.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million); 6.6.8. Denmark; 6.6.8.1. Key country dynamics; 6.6.8.2. Regulatory framework/ reimbursement structure; 6.6.8.3. Target Disease Prevalence; 6.6.8.4. Competitive scenario; 6.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million); 6.7. Asia Pacific; 6.7.1. Japan; 6.7.1.1. Key country dynamics; 6.7.1.2. Regulatory framework/ reimbursement structure; 6.7.1.3. Target Disease Prevalence; 6.7.1.4. Competitive scenario; 6.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million); 6.7.2. China; 6.7.2.1. Key country dynamics; 6.7.2.2. Regulatory framework/ reimbursement structure; 6.7.2.3. Target Disease Prevalence; 6.7.2.4. Competitive scenario; 6.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million); 6.7.3. India; 6.7.3.1. Key country dynamics; 6.7.3.2. Regulatory framework/ reimbursement structure; 6.7.3.3. Target Disease Prevalence; 6.7.3.4. Competitive scenario; 6.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million); 6.7.4. Australia; 6.7.4.1. Key country dynamics; 6.7.4.2. Regulatory framework/ reimbursement structure; 6.7.4.3. Target Disease Prevalence; 6.7.4.4. Competitive scenario; 6.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million); 6.7.5. South Korea; 6.7.5.1. Key country dynamics; 6.7.5.2. Regulatory framework/ reimbursement structure; 6.7.5.3. Target Disease Prevalence; 6.7.5.4. Competitive scenario; 6.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million); 6.7.6. Thailand; 6.7.6.1. Key country dynamics; 6.7.6.2. Regulatory framework/ reimbursement structure; 6.7.6.3. Target Disease Prevalence; 6.7.6.4. Competitive scenario; 6.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million); 6.8. Latin America; 6.8.1. Brazil; 6.8.1.1. Key country dynamics; 6.8.1.2. Regulatory framework/ reimbursement structure; 6.8.1.3. Target Disease Prevalence; 6.8.1.4. Competitive scenario; 6.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million); 6.8.2. Argentina; 6.8.2.1. Key country dynamics; 6.8.2.2. Regulatory framework/ reimbursement structure; 6.8.2.3. Target Disease Prevalence; 6.8.2.4. Competitive scenario; 6.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million); 6.9. MEA; 6.9.1. South Africa; 6.9.1.1. Key country dynamics; 6.9.1.2. Regulatory framework/ reimbursement structure; 6.9.1.3. Target Disease Prevalence; 6.9.1.4. Competitive scenario; 6.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million); 6.9.2. Saudi Arabia; 6.9.2.1. Key country dynamics; 6.9.2.2. Regulatory framework/ reimbursement structure; 6.9.2.3. Target Disease Prevalence; 6.9.2.4. Competitive scenario; 6.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million); 6.9.3. UAE; 6.9.3.1. Key country dynamics; 6.9.3.2. Regulatory framework/ reimbursement structure; 6.9.3.3. Target Disease Prevalence; 6.9.3.4. Competitive scenario; 6.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million); 6.9.4. Kuwait; 6.9.4.1. Key country dynamics; 6.9.4.2. Regulatory framework/ reimbursement structure; 6.9.4.3. Target Disease Prevalence; 6.9.4.4. Competitive scenario; 6.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape: 7.1. Recent Developments & Impact Analysis, By Key Market Participants; 7.2. Company/Competition Categorization; 7.3. Vendor Landscape; 7.3.1. Key company market share analysis, 2024; 7.3.2. Intact Medical Corporation; 7.3.2.1. Company overview; 7.3.2.2. Financial performance; 7.3.2.3. Product benchmarking; 7.3.2.4. Strategic initiatives; 7.3.3. Ethicon Surgical Technologies; 7.3.3.1. Company overview; 7.3.3.2. Financial performance; 7.3.3.3. Product benchmarking; 7.3.3.4. Strategic initiatives; 7.3.4. Gallini SRL; 7.3.4.1. Company overview; 7.3.4.2. Financial performance; 7.3.4.3. Product benchmarking; 7.3.4.4. Strategic initiatives; 7.3.5. Leica Biosystems Nussloch GmbH; 7.3.5.1. Company overview; 7.3.5.2. Financial performance; 7.3.5.3. Product benchmarking; 7.3.5.4. Strategic initiatives; 7.3.6. Hologic, Inc; 7.3.6.1. Company overview; 7.3.6.2. Financial performance; 7.3.6.3. Product benchmarking; 7.3.6.4. Strategic initiatives; 7.3.7. Argon Medical Devices; 7.3.7.1. Company overview; 7.3.7.2. Financial performance; 7.3.7.3. Product benchmarking; 7.3.7.4. Strategic initiatives; 7.3.8. Encapsule Medical Devices LLC; 7.3.8.1. Company overview; 7.3.8.2. Financial performance; 7.3.8.3. Product benchmarking; 7.3.8.4. Strategic initiatives; 7.3.9. Cook Medical Incorporated; 7.3.9.1. Company overview; 7.3.9.2. Financial performance; 7.3.9.3. Product benchmarking; 7.3.9.4. Strategic initiatives; 7.3.10. Becton, Dickinson and Company; 7.3.10.1. Company overview; 7.3.10.2. Financial performance; 7.3.10.3. Product benchmarking; 7.3.10.4. Strategic initiatives; 7.3.11. C.R. Bard, Inc.; 7.3.11.1. Company overview; 7.3.11.2. Financial performance; 7.3.11.3. Product benchmarking; 7.3.11.4. Strategic initiatives